Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Bioneer is a Danish advanced technology company, providing custom development- and analytical services to projects in drug development- and diagnostic companies, academic groups and hospitals. Bioneer is highly specialized within applications of cells, using their extensive knowledge anywhere from disease modeling using pluripotent stem cells and human primary cells; to recombinant protein production and biomarker identification/validation (RNA, DNA, protein) in single-cell- and tissue preparations. Furthermore, Bioneer also offers drug development of small molecules and biologics, from characterization through to a final formulation.

Suzhou Bawei Pharmaceutical Development Research Institute Co., Ltd., established on 2000-04-06, Business scope includes licensed business items:No general operating items:develop,to develop,Production,Sales:Biowave Regulator Products,Products related to biowave theory.

ICCAS was founded in 1956. ICCAS is a multi-disciplinary research institute dedicated to the basic research in broad fields of chemical sciences, and to the key developments of the innovative high technologies aiming to the imperative national needs and important strategic targets, as well as to the collaborative high-technology applications and transfers. ICCAS is one of China’s leading chemistry research institutions with high international reputation.

Medtronic, Inc. operates as a medical technology company. It offers implantable cardiac pacemakers, eternal defibrillators, inferior turbinate surgery products, and continuous glucose monitoring device. The company was founded by Earl E. Bakken and Palmer J. Hermundslie on April 29, 1949 and is headquartered in Minneapolis, MN.

Huzhou Xinchi Pharmaceutical Technology Co., Ltd., established on 2011-03-18, The business scope includes the second,Class III medical device:Medical hygiene materials and dressings,Medical Suture Materials and Adhesives(Remove bone cement),Medical electronic equipment(Except implantable cardiac pacemakers and medical sensors implanted in the body).Medical Optics,Instruments and endoscopic equipment(Except for ophthalmic optical devices implanted in the body or in long-term contact with the body),Physiotherapy and Rehabilitation Equipment,Clinical Laboratory Analytical Instruments,Sales of medical polymer materials and products(<Medical device operating enterprise license>Valid until2016year11moon15day).Pharmaceutical Products and Raw Materials,Research and development of pharmaceutical intermediates,technical consulting,technology transfer,General Machinery,Chemical Products(Removal of hazardous chemicals and precursor chemicals),Class Ι medical device,real estate medicine,Sales of primary agricultural products.